Top View
- Final Scope PDF 170 KB
- Elbasvir/Grazoprevir (Zepatier) Reference Number: ERX.SPMN.181 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- GLASS Methodology for Surveillance of National Antimicrobial Consumption
- Unlabeled/Unapproved Use
- 5.01.606 Hepatitis C Antiviral Therapy
- ZEPATIER Is Recommended
- Elbasvir/Grazoprevir (Zepatier™) Drug Interactions a Quick Guide For
- Screening for Hepatitis C Virus Infection in Adolescents and Adults: a Systematic Review Update for the U.S
- Elbasvir-Grazoprevir (Zepatier)
- HEPATITIS C AGENTS Epclusa (Sofosbuvir & Velpatasvir), Harvoni
- Elbasvir/Grazoprevir (Zepatier) Reference Number: CP.PCH.16 Effective Date: 01.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM Revision Log
- Cp.Pch.15 (Pdf)
- NYSDOH Uninsured Care Programs Covered Services and ADAP
- Daclatasvir, Elbasvir, and Grazoprevir in the Treatment of Chronic Hepatitis C
- Grazoprevir PK Fact Sheet Produced March 2016 Page 1 of 2 for Personal Use Only
- ZEPATIER (Elbasvir/Grazoprevir)
- Russian Pharmaceutical Market 2020 (Pdf, 3.8
- USP Category USP Class Example Part D Eligible Drugs* Salt/Ester
- Daklinza (Daclatasvir)
- Elbasvir/Grazoprevir (Zepatier) Reference Number: NV.PHAR.275 Effective Date: 07/17 Last Review Date: 01/19
- Genotype 1A – No Cirrhosis
- Repurposing 57 Well-Known Drugs for Three COVID-19 Targets: Mpro, Spike, Rdrp
- Treatment of Acute HCV Infection
- Grazoprevir/Elbasvir for the Treatment of Hepatitis C Application for Inclusion on the WHO Model List of Essential Medicines (EML) Contents
- Curing Hepatitis C in the Indian Health Service
- ZEPATIER (Elbasvir and Grazoprevir) Tablets Label
- Remdesivir from Wikipedia, the Free Encyclopedia
- Treatment of HCV Genotype 1
- Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C RANDI SOKOL, MD, MPH, Mmeded, Tufts University Family Medicine Residency Program, Malden, Massachusetts
- ESAC-Net Reporting Protocol 2019.Docx
- Zepatier, INN-Grazoprevir/Elbasvir
- Grazoprevir/Elbasvir
- Grazoprevir/Elbasvir for the Treatment of Adults with Chronic Hepatitis C: a Short Review on the Clinical Evidence and Place in Therapy
- Spotlight on Grazoprevir–Elbasvir Once-Daily Combination and Its Potential in the Treatment of Hepatitis C
- Treatment of HCV Genotype 4
- Zepatier, INN-Grazoprevir/Elbasvir
- REYATAZ (Atazanavir)
- Elbasvir/Grazoprevir (Zepatier) for Hepatitis C Virus Infection JESSICA EARLY, MD, and GEORGE MAXTED, MD, Tufts University School of Medicine, Malden, Massachusetts
- Attachment A)
- Clinical Policy: Elbasvir/Grazoprevir (Zepatier) Reference Number: LA.PHAR.275 Effective Date: 09/16 Last Review Date: 05/18 Revision Log Line of Business: Medicaid
- Treatment of Hepatitis C Hepatitis C (HCV)
- Zepatier™ (Elbasvir/Grazoprevir) Information Packet
- Grazoprevir/Elbasvir in Peginterferon Alfa Plus Ribavirin Experienced Patients with Chronic Genotype 1 HCV/HIV Co-Infection
- Beschlussfassung Der Arbeitsgruppe ATC/DDD Des Kuratoriums Für Fragen Der Klassifikation Im Gesundheitswesen
- ESAC-Net Reporting Protocol 2018.Docx Introduction